Triaging antibody sequences from high-throughput next-generation sequence data for development of effective therapeutics

现在有一类主要的药物是基于抗体的。最近的抗体药物开发方法使用转基因小鼠抗体库的NGS测序，人血清或噬菌体展示，如Kyumab公司每周定期产生10^6个序列。AM的abYsis软件被许多公司用于分析抗体，但不是为这种高通量而设计的。该项目将开发新的软件，允许大型库进行分析和分类（寻找不寻常的功能和可开发性的责任），然后加载到abYsis进行进一步分析，并与FF实验室的BRepertoire接口。

A major class of drugs is now antibody-based. Recent approaches to antibody drugdevelopment use NGS sequencing of antibody libraries from transgenic mice, human serumor phage display with companies such as Kymab regularly generating 10^6 sequences perweek. AM's abYsis software is used by a number of companies to analyze antibodies, but isnot designed for this type of high throughput. The project will develop novel software to allowlarge libraries to be analyzed and triaged (looking for unusual features and developabilityliabilities) before loading into abYsis for further analysis and interface with BRepertoire fromFF's lab.